Ivecas 50 mg, 70 mg Powder for concentrate for solution for infusion.
PDF Leaflet Revision Date: 26 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Empirical therapy for presumed fungal infections and treatment of invasive candidiasis.
Dosage (summary)
70 mg loading dose on Day 1, followed by 50 mg daily.
Special Populations
- Elderly
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Ciclosporin
- Rifampicin
- Dexamethasone
Contraindications
- Hypersensitivity to caspofungin
- Severe hepatic insufficiency
Common side effects
- Hypersensitivity reactions
- Phlebitis
- Nausea
- Headache
Counselling Points
- Monitor for hypersensitivity reactions
- Avoid driving until effects are known
- Inform about potential liver enzyme changes
Serious warnings
- Anaphylaxis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
Important Disclaimer
The Ivecas 50 mg, 70 mg Powder for concentrate for solution for infusion. professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
